KN5501 Cell Injection for Refractory SLE(CLEAR)

Inclusion Criteria: * 1\. Aged 18\~70(including thresholds) when obtaining informed consent; * 2\. Body weight \> 40.0 kg at screening; * 3\. Refractory SLE patients with moderate to severe activity; * 4\. CBC meeting predefined requirements at screening, including ANC ≥ 1.5×10\^9/L, Hb ≥ 80g/L, and PLT ≥ 50×10\^9/L(Not applicable, if it is ITP due to active SLE disease which is judged by investigator); * 5\. Adequate liver, kidney, lung and ;heart function at screening; * 6\. The date of last supportive therapy of hemopoietic growth factor(including EPO, G-CSF, GM-CSF and TPO, etc.)should be at least 2 weeks before screening visit, the last date of PLT infusion should be at least one week before screening visit, and the last date of RBC infusion should be at least 2 weeks before screening visit; * 7\. The number of CD19+ B cells in peripheral blood \> 5 cells per microliter at screening; * 8\. Negative serum pregnancy test for WOCBPs at screening. Male or Female trial participants of child bearing potential should utilize efficient contraceptive measures from ICF signing until at least one year since the last dose, and promise not to donate ovums or sperms until at least one year since the last dose. Exclusion Criteria: * 1\. Hypersensitive or allergic to any components of KN5501(e.g. DEXTRAN 40) or other trial interventions including fludarabine, cyclophosphamide, and tocilizumab, or having ever experienced severe anaphylaxis; * 2\. Severe lupus nephritis patients, defin…